Is there a generic version of vortioxetine yet?
Yes. Vortioxetine (an antidepressant marketed under brand names such as Brintellix/Trintellix in different countries) has generic availability in multiple markets, depending on local patent status and what exclusivities apply there.
What does patent status mean for when generics can launch?
A generic can typically enter only after the brand’s legal protection ends for the specific country and product. That protection can include:
- Primary drug substance or composition patents
- Formulation patents (specific formulations/dosage forms)
- Method-of-use patents (less common for broad antidepressant indications)
- Regulatory exclusivities (where applicable in that jurisdiction)
So even if a generic launches in one country, another country can still remain protected until its own patent/exclusivity deadlines.
When do vortioxetine patents expire (by country)?
Patent expiry dates for vortioxetine vary by jurisdiction because filings, claim scope, patent terms, and extensions differ across regions. To determine the actual expiry for your location, you need:
- The country (or region) where you’re buying or comparing availability
- The specific brand name/formulation (e.g., tablets, strength)
- Whether your local listing shows additional patents or only the core compound patent
How can you check your local generic availability quickly?
The most reliable way is to check the regulator’s “generic/substitutable” listings for your country and match them to the product strength and dosage form. Then cross-check with patent registers if you need the legal reason for delays in other markets.
Why might a generic appear later than you expect?
Common reasons include:
- Still-pending patents in that country (even if compound patents expired elsewhere)
- Different formulation protections (a generic might be blocked for specific strengths/forms)
- Exclusivity rules tied to data protection or marketing authorization status
If you tell me your country, can you narrow it down?
Yes. Share your country (and the brand strength, if you know it, like 5 mg/10 mg/20 mg), and I can focus on the relevant patent/exclusivity window and what that implies for when generics can be expected in that market.